Mutation-specific therapies that potentiate cystic fibrosis transmembrane conductance regulator (CFTR) function in cystic fibrosis
Authors:
- 16 May 2012
- reference entry
- Published by Wiley
- No. 5
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway InfectionChest, 2009
- Molecular targeting of CFTR as a therapeutic approach to cystic fibrosisTrends in Pharmacological Sciences, 2007
- Cystic Fibrosis and Formes Frustes of CFTR-Related DiseaseRespiration, 2007
- Cystic fibrosis: disease mechanisms and therapeutic targetsDrug Discovery Today: Disease Mechanisms, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- The Phenotypic Consequences of CFTR MutationsAnnals of Human Genetics, 2003
- Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screeningHuman Mutation, 2002
- Comparison of the clinical manifestations of cystic fibrosis in black and white patientsThe Journal of Pediatrics, 1998
- Delta F508 in cystic fibrosis: willing but not ableArchives of Disease in Childhood, 1997
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989